Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer and Sanofi-Aventis have received a positive opinion from an advisory committee to the European Medicines Agency recommending approval of their inhalable insulin product, Exubera, for the treatment of diabetes.
Subscribe to our email newsletter
The Committee for Medicinal Products for Human Use, a division of the European Medicines Agency, issued the positive opinion, which is likely to be acted upon by the European Commission to make Exubera available for type 1 and 2 diabetes sufferers. The move follows similar recommendations made in the US.
Exubera, the product of a joint-development program between sanofi-aventis and Pfizer, is an inhaled rapid-acting insulin preparation that is inhaled into the lungs prior to each meal, using a proprietary inhalation device and powdered insulin formulation developed by Nektar Therapeutics.
Pending approval, Exubera would represent a major advance in insulin delivery and would be the first non-injectable insulin available in Europe since the discovery of insulin in the 1920s. Due to the revolutionary nature of Exubera; it may potentially overcome the need for repeated insulin injections; analysts have estimated worldwide sales of could reach as much as $2 billion a year.
In Europe, approximately 22.5 million people suffer from diabetes. Type 2 diabetes accounts for 85 to 95% of all diagnosed cases.